ADMA Biologics Secures Fifth ASCENIV Approval Letter, FDA Extends Lot Expiry

ADMA Biologics, Inc. has received its fifth FDA approval letter for ASCENIV (Immune Globulin Intravenous, Human-slra, 10% Liquid) as of April 30, 2026, signaling an active post-approval regulatory relationship that biologics manufacturers should note as a reference point for long-cycle product maintenance under 21 CFR Part 600 and GMP frameworks governing blood-derived biologics.

ASCENIV carries STN 125590 and is indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. The product's approval history spans from its original April 1, 2019 letter through subsequent actions in December 2022, September 2023, March 2024, and now April 2026, reflecting a sustained cadence of post-approval submissions and regulatory reviews that QA and regulatory affairs teams should factor into lifecycle planning models.

Alongside the latest approval letter, FDA has granted an expiration date extension for six ASCENIV lots manufactured in 2019 and 2020. For sterility assurance leads and batch release teams, lot expiration extensions of this duration represent a meaningful shelf-life management consideration, requiring documented stability data packages that satisfy FDA's biologics post-approval standards. The extension underscores the regulatory pathway available to manufacturers holding aging inventory, provided supporting data meets agency expectations.

For plant heads overseeing biologics fill-finish and QA directors managing batch disposition, the ASCENIV record illustrates how a single licensed biologic can generate multiple discrete regulatory touchpoints across its commercial life. Maintaining audit-ready documentation for each approval cycle, including demographic subgroup data referenced in clinical review memos, is a compliance baseline that the ASCENIV dossier publicly demonstrates. Source: FDA Vaccines, Blood and Biologics product page for ASCENIV, updated May 4, 2026.